Cargando…

In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features

BACKGROUND: The development of molecularly tailored therapeutic agents such as the BCR/ABL-active tyrosine kinase inhibitors (TKi) resulted in an excellent treatment option for chronic myeloid leukemia (CML) patients. However, following TKi discontinuation, disease relapses in 40–60% of patients, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tusa, Ignazia, Cheloni, Giulia, Poteti, Martina, Silvano, Angela, Tubita, Alessandro, Lombardi, Zoe, Gozzini, Antonella, Caporale, Roberto, Scappini, Barbara, Dello Sbarba, Persio, Rovida, Elisabetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568716/ https://www.ncbi.nlm.nih.gov/pubmed/32780298 http://dx.doi.org/10.1007/s11523-020-00741-x

Ejemplares similares

Glutamine Availability Controls BCR/Abl Protein Expression and Functional Phenotype of Chronic Myeloid Leukemia Cells Endowed with Stem/Progenitor Cell Potential
por: Poteti, Martina, et al.
Publicado: (2021)

Beyond Kinase Activity: ERK5 Nucleo-Cytoplasmic Shuttling as a Novel Target for Anticancer Therapy
por: Tubita, Alessandro, et al.
Publicado: (2020)

Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells
por: Tusa, Ignazia, et al.
Publicado: (2018)

Lactate Maintains BCR/Abl Expression and Signaling in Chronic Myeloid Leukemia Cells Under Nutrient Restriction
por: Silvano, Angela, et al.
Publicado: (2022)

The Hedgehog-GLI Pathway Regulates MEK5-ERK5 Expression and Activation in Melanoma Cells
por: Tusa, Ignazia, et al.
Publicado: (2021)

Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells
por: Barbetti, Valentina, et al.
Publicado: (2013)

Correction to Barbetti V, et al. Epigenetics Volume 8, Issue 2; pp. 210–9
por: Barbetti, Valentina, et al.
Publicado: (2013)

The Leukemic Stem Cell Niche: Adaptation to “Hypoxia” versus Oncogene Addiction
por: Cheloni, Giulia, et al.
Publicado: (2017)

The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy
por: Rovida, Elisabetta, et al.
Publicado: (2014)

One more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a “hypoxic” environment
por: Rovida, Elisabetta, et al.
Publicado: (2014)

Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
por: Tubita, Alessandro, et al.
Publicado: (2022)

Playing the Whack-A-Mole Game: ERK5 Activation Emerges Among the Resistance Mechanisms to RAF-MEK1/2-ERK1/2- Targeted Therapy
por: Tubita, Alessandro, et al.
Publicado: (2021)

Pathophysiological Impact of the MEK5/ERK5 Pathway in Oxidative Stress
por: Tusa, Ignazia, et al.
Publicado: (2023)

The Culture-Repopulating Ability Assays and Incubation in Low Oxygen: A Simple Way to Test Drugs on Leukaemia Stem or Progenitor Cells
por: Cipolleschi, Maria Grazia, et al.
Publicado: (2013)

Chronic Myeloid Leukemia and Hepatoblastoma: Two Cancer Models to Link Metabolism to Stem Cells
por: Cipolleschi, Maria Grazia, et al.
Publicado: (2016)

Hypoxia Selects Bortezomib-Resistant Stem Cells of Chronic Myeloid Leukemia
por: Tanturli, Michele, et al.
Publicado: (2011)

Sensitivity to imatinib of KCL22 chronic myeloid leukemia cell survival/growth and stem cell potential under glucose shortage
por: Bono, Silvia, et al.
Publicado: (2018)

AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia
por: Barbetti, V, et al.
Publicado: (2013)

Targeting MAPK in Cancer 2.0
por: Rovida, Elisabetta, et al.
Publicado: (2022)

The Colony-Stimulating Factor-1 (CSF-1) Receptor Sustains ERK1/2 Activation and Proliferation in Breast Cancer Cell Lines
por: Morandi, Andrea, et al.
Publicado: (2011)

Low-dose methotrexate enhances cycling of highly anaplastic cancer cells
por: Cipolleschi, Maria Grazia, et al.
Publicado: (2016)

Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures
por: Masala, Erico, et al.
Publicado: (2018)

Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model
por: Lindström, H. Jonathan G., et al.
Publicado: (2022)

Different BCR/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction
por: Bono, Silvia, et al.
Publicado: (2016)

ERK5 is activated by oncogenic BRAF and promotes melanoma growth
por: Tusa, Ignazia, et al.
Publicado: (2018)

The complex metabolic network gearing the G(1)/S transition in leukemic stem cells: Hints to a rational use of antineoplastic agents
por: Stivarou, Theodora, et al.
Publicado: (2015)

Cancer stemness and progression: mitochondria on the stage
por: Chiarugi, Paola, et al.
Publicado: (2015)

Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016)

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
por: Pouwer, Marianne G., et al.
Publicado: (2018)

Chronic myeloid leukemia progenitor cells require autophagy when leaving hypoxia-induced quiescence
por: Ianniciello, Angela, et al.
Publicado: (2017)

Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia
por: Kantarjian, Hagop M., et al.
Publicado: (2022)

Cutaneous Lesions Anticipating Accelerated Phase of Multidrug Resistant Chronic Myeloid Leukemia Responsive to Ponatinib
por: Breccia, Massimo, et al.
Publicado: (2016)

Hypoxia-resistant profile implies vulnerability of cancer stem cells to physiological agents, which suggests new therapeutic targets
por: Cipolleschi, Maria Grazia, et al.
Publicado: (2014)

Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells
por: Hallal, Rawan, et al.
Publicado: (2020)

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
por: Oaxaca, Derrick M., et al.
Publicado: (2016)

S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL
por: Jabbour, Elias, et al.
Publicado: (2023)

Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells
por: Barbetti, V, et al.
Publicado: (2014)

Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia
por: Price, Kimberly E, et al.
Publicado: (2013)

A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia
por: Korfi, K., et al.
Publicado: (2015)

Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia
por: Musumeci, Francesca, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fe8cocdp5lshj8dkic6itsl9di